Risk assessment of thromboembolic events in hospitalized cancer patients

Nichetti, Federico; Ligorio, Francesca; Montelatici, Giulia; Porcu, Luca; Zattarin, Emma; Provenzano, Leonardo; Franza, Andrea; Lalli, Luca; Braud, Filippo de; Platania, Marco

doi:10.1038/s41598-021-97659-9

Cited by 6 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the overall prevalence of thromboembolic events was 17 (6.8%), of which most (9, 52.9%) were in the form of pulmonary embolism. The study result was higher than the results of studies conducted in America (4.1%) ( 41 ) and Italy (5.4%) ( 42 ) but was lower than a study conducted in the United States (8.4%) ( 43 ). A study by Khorana et al.…”

Section: Discussioncontrasting

confidence: 80%

Evaluation of thromboembolic event, basic coagulation parameters, and associated factors in patients with colorectal cancer: a multicenter study

et al. 2023

View full text Add to dashboard Cite

BackgroundPatients with colorectal cancer are at an increased risk of hemostatic disturbances, and recent studies have shown that coagulation disorders could be the first sign of malignancy. Although coagulopathy is a significant cause of cancer-related death and disability, it is usually underestimated, and there has been no recent scientific evidence regarding the exact burden and its specific determinants. Moreover, the public health importance of the risk of coagulopathy among patients with colorectal polyps has not been addressed.Materials and methodsAn institution-based comparative cross-sectional study was conducted on a total of 500 study participants (250 colorectal cancer patients, 150 colorectal polyp patients, and 100 controls) from January to December 2022. Venous blood was collected for basic coagulation and platelet analysis. Descriptive statistics and non-parametric tests (Kruskal–Wallis and Dunn–Bonferroni pairwise comparisons) were used to compare study parameters among the groups. The test results were expressed as medians and interquartile ranges. Binary logistic regressions were fitted, and statistical significance was declared at a p-value of less than 0.05, with 95% CI.ResultsThe prevalence of coagulopathy among colorectal cancer patients was 198 (79.2%; 95% CI: 73.86, 83.64), while the prevalence was 76 (50.7%; 95% CI: 45.66, 54.34) among colorectal polyp patients. From the final model, age between 61 and 70 (AOR = 3.13: 95% CI: 1.03, 6.94), age > 70 years (AOR = 2.73: 95% CI: 1.08, 4.71), hypertension (AOR = 6.8: 95% CI: 1.07, 14.1), larger tumor size (AOR = 3.31: 95% CI: 1.11, 6.74), metastatic cancer (AOR = 5.8: 95% CI: 1.1, 14.7), and BMI ≥30 kg/m2 (AOR = 3.8: 95% CI: 2.3, 4.8) were positively associated with coagulopathy.ConclusionThis study showed that coagulopathy is a major public health concern among patients with colorectal cancer. Therefore, existing oncology care efforts should be strengthened to prevent coagulopathy among patients with colorectal cancer. Moreover, patients with colorectal polyps should receive more attention.

show abstract

Section: Discussioncontrasting

confidence: 80%

Evaluation of thromboembolic event, basic coagulation parameters, and associated factors in patients with colorectal cancer: a multicenter study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Two retrospective cohort studies have established that a Khorana score of ≥2 predicts inpatient VTE. 27,28 A recent prospective observational study named INDICATE study by Nichetti et al 21 showed a 95.4% NPV for VTE with a Khorana score of 0. However, it did not show any significant association of a higher Khorana VTE score with an increased VTE risk in hospitalized cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Venous Thromboembolism Risk Assessment in Hospitalized Cancer Patients: A Single Center Study

Rayamajhi,

Shrotriya,

Rai

et al. 2023

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

This study aimed to identify predictors of venous thromboembolism (VTE) in hospitalized cancer patients and develop a predictive model using demographic, clinical, and laboratory data. Our analysis showed that patient groups categorized under a very high risk, and high risk, patients with low hemoglobin levels and renal disease were at a significantly increased risk of developing VTE. We developed a VTE risk-assessment model (RAM) with moderate discriminatory performance, high specificity, and negative predictive value, indicating its potential utility in identifying patients without VTE risk. However, the model's positive predictive value and sensitivity were low due to the low prevalence of VTE within the analyzed population. Future studies are needed to analyze additional predictive factors, and to validate the effectiveness of our VTE RAM to safely rule out VTE, compare it with other VTE RAMs in hospitalized cancer patients, and address any limitations of our study.

show abstract

“…Although out of the scope of this study, KS ≥ 3 was found to predict a worse prognosis (≥ 3 vs. < 3, log-rank test, P = 0.046). Overall, data on the discriminatory performance of KS among cancer patients is inconsistent 20 , 47 , 48 . Further investigation is, however, required to validate these findings among CC patients, particularly in larger cohorts and considering other treatments.…”

Section: Discussionmentioning

confidence: 99%

Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer

Neto

Tavares

Silva

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a leading cause of death among cancer patients. Khorana score (KS) is the most studied tool to predict cancer-related VTE, however, it exerts poor sensitivity. Several single-nucleotide polymorphisms (SNPs) have been associated with VTE risk in the general population, but whether they are predictors of cancer-related VTE is a matter of discussion. Compared to other solid tumours, little is known about VTE in the setting of cervical cancer (CC) and whether thrombogenesis-related polymorphisms could be valuable biomarkers in patients with this neoplasia. This study aims to analyse the effect of VTE occurrence on the prognosis of CC patients, explore the predictive capability of KS and the impact of thrombogenesis-related polymorphisms on CC-related VTE incidence and patients’ prognosis regardless of VTE. A profile of eight SNPs was evaluated. A retrospective hospital-based cohort study was conducted with 400 CC patients under chemoradiotherapy. SNP genotyping was carried on by using TaqMan® Allelic Discrimination methodology. Time to VTE occurrence and overall survival were the two measures of clinical outcome evaluated. The results indicated that VTE occurrence (8.5%) had a significant impact on the patient’s survival (log-rank test, P < 0.001). KS showed poor performance (KS ≥ 3, χ2, P = 0.191). PROCR rs10747514 and RGS7 rs2502448 were significantly associated with the risk of CC-related VTE development (P = 0.021 and P = 0.006, respectively) and represented valuable prognostic biomarkers regardless of VTE (P = 0.004 and P = 0.010, respectively). Thus, thrombogenesis-related genetic polymorphisms may constitute valuable biomarkers among CC patients allowing a more personalized clinical intervention.

show abstract

Risk assessment of thromboembolic events in hospitalized cancer patients

Cited by 6 publications

References 34 publications

Evaluation of thromboembolic event, basic coagulation parameters, and associated factors in patients with colorectal cancer: a multicenter study

Evaluation of thromboembolic event, basic coagulation parameters, and associated factors in patients with colorectal cancer: a multicenter study

Venous Thromboembolism Risk Assessment in Hospitalized Cancer Patients: A Single Center Study

Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer

Contact Info

Product

Resources

About